Format

Send to

Choose Destination
J Clin Exp Neuropsychol. 2010 Apr;32(4):337-49. doi: 10.1080/13803390903042361.

Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor.

Author information

1
Department of Psychiatry, University of California San Diego, San Diego, CA, USA. klhanson@ucsd.edu

Abstract

BACKGROUND:

MDMA (3,4-methylenedioxymethamphetamine; "Ecstasy") is an amphetamine derivative with mild hallucinogenic and stimulant qualities. MDMA leads to serotonin (5-hydroxytryptamine; 5-HT) neurotoxicity and has been linked to cognitive impairments. It remains unclear whether these impairments are due to MDMA versus other drug use.

METHOD:

Neurocognitive functioning was measured in a sample of abstinent polydrug users (n = 52) with a range of MDMA use and healthy nondrug controls (n = 29). Participants completed a comprehensive neuropsychological battery and self-report measures of drug use.

RESULTS:

Polydrug users performed worse than controls on spatial span and spatial working memory (ps < .05). Among polydrug users, lifetime marijuana use significantly predicted verbal learning and memory performance (p < .01), while MDMA use was not predictive of cognitive impairment.

CONCLUSIONS:

This study and our previous report (Hanson, Luciana, & Sullwold, 2008) suggest that moderate MDMA use does not lead to persistent impairments above and beyond that associated with generally heavy drug use, but polydrug use may lead to dose-related temporal and frontoparietal dysfunction. Marijuana use may be particularly problematic. Cause-effect relations are unclear.

PMID:
20397296
DOI:
10.1080/13803390903042361
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center